Valuation: AnaptysBio, Inc.

Market Cap 1.65B 1.44B 1.33B 1.23B 2.32B 159B 2.36B 15.91B 6.24B 77.73B 6.21B 6.07B 268B P/E 2026 *
-226x
P/E 2027 * 14x
Enterprise Value 1.56B 1.36B 1.26B 1.16B 2.19B 150B 2.23B 15.03B 5.9B 73.39B 5.86B 5.73B 253B EV / Sales 2026 *
16.6x
EV / Sales 2027 * 8.88x
Free-Float
94.32%
Yield 2026 *
-
Yield 2027 * -
1 day-0.70%
1 week-15.54%
Current month-16.68%
1 month-2.38%
3 months-15.93%
6 months+23.12%
Current year+16.01%
1 week 54.44
Extreme 54.44
70.91
1 month 54.44
Extreme 54.44
70.91
Current year 42
Extreme 42
73.3
1 year 17.11
Extreme 17.1062
73.3
3 years 12.21
Extreme 12.21
73.3
5 years 12.21
Extreme 12.21
73.3
10 years 10
Extreme 10
134
Manager TitleAgeSince
Chief Executive Officer 46 2022-03-20
Director of Finance/CFO 42 2026-05-10
Corporate Officer/Principal 35 2021-12-31
Director TitleAgeSince
Director/Board Member 79 2015-06-29
Director/Board Member 63 2015-06-29
Director/Board Member 49 2021-04-07
Date Insider Type Main position Quantity % Market Cap.
06-14Fiscal year

Director

12,060 0.0414%
06-14Fiscal year

Chairman

12,060 0.0414%
06-14Fiscal year

Director

12,060 0.0414%
Change 5-day change 1-year change 3-year change Capi.($)
-0.70%-15.54%+109.38%+199.63% 1.65B
+3.13%+13.95%+64.21%+94.35% 57.82B
+0.40%-5.42%+55.06%+72.21% 53.71B
-1.95%-9.48%+2.35%+417.15% 23.8B
+0.30%-0.96%-18.13%-14.10% 23.26B
-0.56%+6.10%+44.56%-3.75% 20.7B
-1.20%-3.29%+32.71%-30.51% 17.81B
+10.00%-4.30%+208.33%+370.99% 16.9B
-2.61%+10.00%+47.02%+699.54% 16.36B
+2.02%-1.24%+25.84%+193.85% 13.96B
Average +0.90%-0.18%+57.13%+199.94% 24.6B
Weighted average by Cap. +1.17%+1.24%+51.39%+158.81%

Financials

2026 *2027 *
Net sales 94.28M 82.43M 76.04M 69.9M 132M 9.07B 135M 908M 356M 4.43B 354M 346M 15.28B 153M 134M 124M 114M 215M 14.74B 219M 1.48B 579M 7.2B 575M 563M 24.83B
Net income -7.47M -6.53M -6.02M -5.54M -10.49M -719M -10.67M -71.9M -28.21M -351M -28.04M -27.43M -1.21B 129M 113M 104M 95.43M 181M 12.38B 184M 1.24B 486M 6.05B 483M 473M 20.86B
Net Debt -92.22M -80.63M -74.38M -68.38M -130M -8.87B -132M -888M -348M -4.34B -346M -339M -14.95B -293M -256M -236M -217M -412M -28.2B -419M -2.82B -1.11B -13.78B -1.1B -1.08B -47.5B
Logo AnaptysBio, Inc.
AnaptysBio, Inc. is a royalty management company. The Company manages the financial collaborations for Jemperli with GlaxoSmithKline (GSK) and imsidolimab with Vanda Pharmaceuticals Inc. (Vanda). The Company's financial collaboration with GSK is focused upon the development and commercialization of Anaptys-discovered Jemperli (dostarlimab), a PD-1 antagonist, approved for endometrial cancer and dMMR pan tumors, and is being studied in rectal cancer, colon cancer and head and neck squamous cell carcinoma. The Company's financial collaboration with Vanda is focused upon the development and commercialization of Anaptys-discovered imsidolimab, an IL-36R antagonist, which is being developed for generalized pustular psoriasis (GPP).
Employees
104
Date Price Change Volume
26-07-16 US$56.32 +0.90% 77,974
26-07-15 US$55.82 -10.70% 1,546,208
26-07-14 US$62.51 -10.46% 623,074
26-07-13 US$69.81 +5.15% 840,574
26-07-10 US$66.39 -0.30% 401,063
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
55.82USD
Average target price
87.09USD
Spread / Average Target
+56.02%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ANAB Stock